Traditional cures-maker Bohai ready for liftoff as China expands healthcare

Traditional Chinese medicine maker Bohai Pharmaceuticals has been grabbing headlines lately as well as the interest of investors. The company added five products to its offerings this month: three prescription drugs and two OTC medicines. Investor interest is piqued by ambitious Chinese government healthcare reforms that aim to make such drugs affordable to the rural poor--the majority of China's population. Article

Suggested Articles

Dr. Reddy’s says it has been told the FDA will not take regulatory action at its sterile formulations plant in Duvvada, Visakhapatnam.

The end is near for a GlaxoSmithKline OTC plant in Pennsylvania and its 260 employees. In fact, it has a date. 

The FDA is bracing for drug and medical supply shortages in the U.S. as the COVID-19 outbreak from China continues to spread globally.